| Literature DB >> 28687661 |
Jue Hou1, Shuhui Wang1, Manxue Jia1, Dan Li1, Ying Liu1, Zhengpeng Li1, Hong Zhu2, Huifang Xu2, Meiping Sun3, Li Lu3, Zhinan Zhou3, Hong Peng1, Qichen Zhang1, Shihong Fu4,5, Guodong Liang4,5, Lena Yao6, Xuesong Yu6, Lindsay N Carpp6, Yunda Huang6, Julie McElrath6, Steve Self6, Yiming Shao7,8.
Abstract
In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity. We conducted a cohort study in which 21 healthy subjects in China were administered one dose of the YF-17D vaccine; PBMCs were collected at 0 h and then at 4 h and days 1, 2, 3, 5, 7, 14, 28, 84, and 168 postvaccination, and analyzed by transcriptional profiling and immunological assays. At 4 h postvaccination, genes associated with innate cell differentiation and cytokine pathways were dramatically downregulated, whereas receptor genes were upregulated, compared with their baseline levels at 0 h. Immune response pathways were primarily upregulated on days 5 and 7, accompanied by the upregulation of the transcriptional factors JUP, STAT1, and EIF2AK2. We also observed robust activation of innate immunity within 2 d postvaccination and a durable adaptive response, as assessed by transcriptional profiling. Coexpression network analysis indicated that lysosome activity and lymphocyte proliferation were associated with dendritic cell (DC) and CD4+ T cell responses; FGL2, NFAM1, CCR1, and TNFSF13B were involved in these associations. Moreover, individuals who were baseline-seropositive for Abs against another flavivirus exhibited significantly impaired DC, NK cell, and T cell function in response to YF-17D vaccination. Overall, our findings indicate that YF-17D vaccination induces a prompt innate immune response and DC activation, a robust Ag-specific T cell response, and a persistent B cell/memory B cell response.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28687661 PMCID: PMC6681914 DOI: 10.4049/jimmunol.1700083
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422